FDA panel backs more restricted hydrocodone prescribing

Rheumatology News:

At the end of a 2-day meeting on Jan. 25, the FDA’s Drug Safety and Risk Management Advisory Committee voted 19 to 10 that these products should be rescheduled from schedule III under the Controlled Substances Act (CSA), to schedule II.

  • Schedule II: Must be handwritten.
  • Schedule III: Can be called in and have up to 5 monthly refills.

From the same article:

Almost all (99%) of hydrocodone used in the world is in the United States, where hydrocodone combination products are the most widely prescribed products